International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis - BILA-4124/PED
Latest Information Update: 06 Feb 2026
At a glance
- Drugs Bilastine (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors FAES Farma
Most Recent Events
- 06 Feb 2026 route of the drug assumed from RDI
- 06 Feb 2026 New trial record